Clinical Trial Update: Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating cabozantinib in combination with atezolizumab versus a second hormonal therapy in metastatic castration-resistant prostate cancer has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• cabozantinib (cabozantinib)

Snippet

Sponsor: Exelixis | Conditions: Metastatic Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-18